Case Study: DOXIL, the Development of Pegylated Liposomal Doxorubicin

Injectable Dispersed Systems: Formulation, Processing, and Performance

Volumn , Issue , 2005, Pages 427-480

  Martin, Frank J ^a  

^a ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054697475     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780849350610-18     Document Type: Chapter

References (87)

1. Gabizon A. Liposomal anthracyclines. New Drug Ther 1994; 8:431-450.
2. Gabizon A, Chisin R, Amselem S, et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer 1991; 64(6):1125-1132.
3. Liu D, Liu F, Song YK. Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin. Biochim Biophys Acta 1995; 1235(1):140-146.
4. Gregoriadis G, Senior J. Control of fate and behaviour of liposomes in vivo. Prog Clin Biol Res 1982; 102(A):263-279.
5. Proffitt RT, Williams LE, Presant CA, et al. Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice. J Nucl Med 1983; 24(1):45-51.
6. Gill PS, Espina BM, Muggia F, et al. Phase II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995; 13(4):996-1003.
7. Papahadjopoulos D, Gabizon A. Liposomes designed to avoid the reticuloendothelial system. Prog Clin Biol Res 1990; 343:85-93.
8. Gabizon A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989; 81(19):1484-1488.
9. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85(18):6949-6953.
10. Allen TM, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 1987; 223(1):42-46.
11. Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993; 10(5):703-708.
12. Cowens JW, Creaven PJ, Greco WR, et al. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993; 53(12):2796-2802.
13. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54(4):987-992.
14. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003; 21(7):1404-1411.
15. Sleel RT. Chemotherapeutic and biologic agents. In: Skeel RT, ed. Handbook of Cancer Chemotherapy. Boston: A Little Brown, 1991:77-140.
16. Fischl MA, Krown SE, O’Boyle KP, et al. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi’s sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 1993; 6(3):259-264.
17. Gazit Y, Baish JW, Safabakhsh N, et al. Fractal characteristics of tumor vascular architecture during tumor growth and regression. Microcirculation 1997; 4(4):395-402.
18. Yuan F, Leunig M, Huang SK, et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54(13):3352-3356.
19. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987; 6(4):559-593.
20. Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 1992; 9(2):135-187.
21. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54(suppl 4):1-7.
22. Anders RJ, Shanes JG, Zeller FP. Lower incidence of doxorubicin- induced cardiomyopathy by once-a-week low-dose administration. Am Heart J 1986; 111(4):755-759.
23. Shapira J, Gotfried M, Lishner M, et al. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990; 65(4):870-873.
24. Valdivieso M, Burgess MA, Ewer MS, et al. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J Clin Oncol 1984; 2(3):207-214.
25. Lum BL, Svec JM, Torti FM. Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity. Drug Intell Clin Pharm 1985; 19(4):259-264.
26. Goren D, Gabizon A, Barenholz Y. The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior. Biochim Biophys Acta 1990; 1029(2):285-294.
27. Olson F, Mayhew E, Maslow D, et al. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol 1982; 18(2):167-176.
28. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1996; 14(8):2353-2364.
29. Kanter PM, Bullard GA, Pilkiewicz FG, et al. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99):comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo 1993; 7(1):85-95.
30. Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am 1994; 8(2):431-450.
31. Conley BA, Egorin MJ, Whitacre MY, et al. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. Cancer Chemother Pharmacol 1993; 33(2):107-112.
32. Presant CA, Proffitt RT, Turner AF, et al. Successful imaging of human cancer with indium-111-labeled phospholipid vesicles. Cancer 1988; 62(5):905-911.
33. Gregoriadis G, Senior J. The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation. FEBS Lett 1980; 119(1):43-46.
34. Juliano RL, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun 1975; 63(3):651-658.
35. Presant CA, Scolaro M, Kennedy P, et al. Liposomal daunorubicin treatment of HIV-associated Kaposi’s sarcoma. Lancet 1993; 341(8855):1242-1243.
36. Lasic DD, Martin FJ, Gabizon A, et al. Sterically stabilized liposomes:a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991; 1070(1):187-192.
37. Allen TM, Hansen C, Martin F, et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991; 1066(1):29-36.
38. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996; 36(1):55-63.
39. Amantea MA, Forrest A, Northfelt DW, et al. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma. Clin Pharmacol Ther 1997; 61(3):301-311.
40. Clerc S, Barenholz Y. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Biochim Biophys Acta 1995; 1240(5):257-265.
41. Szoka F, Olson F, Heath T, et al. Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim Biophys Acta 1980; 601(3):559-571.
42. Lasic DD, Frederik PM, Stuart MC, et al. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett 1992; 312(2-3):255-258.
43. Huang SK, Martin FJ, Jay G, et al. Extravasation and transcytosis of liposomes in Kaposi’s sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 1993; 143(1):10-14.
44. Huang SK, Lee KD, Hong K, et al. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992; 52(19):5135-5143.
45. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88(24):11460-11464.
46. Huang S, Mayhew E, Gilani S, et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52:6774-6781.
47. Vaage J, Barbera-Guillem E, Abra R, et al. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994; 73(5):1478-1484.
48. Vaage J, Donovan D, Mayhew E, et al. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993; 72(12):3671-3675.
49. Williams SS, Alosco TR, Mayhew E, et al. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 1993; 53(17):3964-3967.
50. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54:987-992.
51. Northfelt D, Martin F, et al. Pharmacokinetics (PK), tumor localization (TL), and safety of Doxil (liposomal doxorubicin) in AIDS patients with Kaposi’s sarcoma (AIDS-KS). Proc Am Soc Clin Oncol 1993; 12.
52. Northfelt DW. Stealth liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-Kaposi’s sarcoma (AIDSKS) lesions than to normal skin (Meeting abstract). Proc Am Soc Clin Oncol 1994; 13.
53. Northfelt D, Kaplan L, et al. Pharmacokinetics and tumor localization of DOX-SL (Stealth liposomal doxorubicin) by comparison with adriamycin in patients with AIDS and Kaposi’s sarcoma. In: Lasic D, Martin F, eds. Stealth Liposomes. Boca Raton, FL: CRC Press, 1995.
54. Northfelt DW, Martin FJ, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996; 36(1):55-63.
55. Sturzl M, Zietz C, Eisenburg B, et al. Liposomal doxorubicin in the treatment of AIDS-associated Kaposi’s sarcoma: clinical, histological and cell biological evaluation. Res Virol. 1994; 145(3-4):261-269.
56. Bogner JR, Kronawitter U, Rolinski B, et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 1994; 7(5):463-468.
57. Gruenaug M, Bogner JR, Loch O, et al. Liposomal doxorubicin in pulmonary Kaposi’s sarcoma: improved survival as compared to patients without liposomal doxorubicin. Int Conf AIDS 1996; 11(1):303 (abstract no. Tu.B2221).
58. Goebel FD, Bogner JR, Spathling S, et al. Efficacy and toxicity of liposomal doxorubicin in advanced AIDS-related Kaposi sarcoma (KS). An open study. Int Conf AIDS 1993; 9(1):58 (abstract no. WS-B15-6).
59. Goebel FD, Liebschwager M, Held M, et al. Successful treatment of advanced Kaposi sarcoma (KS) with liposomal doxorubicin-short term observations. Int Conf AIDS 1992; 8(2):B105 (abstract no. PoB 3108).
60. Goebel FD, Gruenaug M, Bogner JR. Survival times of patients with AIDS-related Kaposi’s sarcoma with pulmonary involvement using liposomal doxorubicin (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1996; 15.
61. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998; 16(2):683-691.
62. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1995; 13(4):914-920.
63. Northfelt D, Stewart S. DOXIL (pegylated liposomal doxorubicin) as first-line therapy of AIDS-related Kaposi’s sarcoma (KS): integrated efficacy and safety results from two comparative trials. Fourth Conf Retro and Opportun Infect 1997; 200 (abstract no. 736).
64. Symon Z, Peyser A, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999; 86(1):72-78.
65. Harrington KJ, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001; 7(2):243-254.
66. Koukourakis MI, Koukouraki S, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas- rationale for combination with radiotherapy. Acta Oncol 2000; 39(2):207-211.
67. Schueller J, C MMC, et al. Serum and tissue kinetics of liposomal encapsulated doxorubicin (Caelyx) in advanced breast cancer patient. Proceedings of the 24th Annual San Antonio Breast Cancer Symposium, 2001; Abstract 436.
68. Koukourakis MI, Koukouraki S, et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 2000; 83(10):1281-1286.
69. Mayer LD, Hope MJ, Cullis PR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 1986; 858(1):161-168.
70. Vaage J, Barbera-Guillem E, Abra R, et al. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994; 73:1478-1484.
71. Amantea M, Forrest A, Northfelt D, et al. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma. Am Soc Clin Pharmacol Ther 1997; 61:301-311.
72. Gbizon A, Shmeeda H, et al. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42(5):419-436.
73. McGuire S. Saquinavir gets accelerated approval. Posit Aware 1996; 7(1):8.
74. Majchrowicz M. DOX-SL: KS treatment in limbo. PI Perspect; 1995(16):13-14.
75. Baker R. Early approval for two lipid-based drugs. Beta 1995:4.
76. Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin. Annal Oncol 1998; 9:711-716.
77. Northfelt DW, Dezube B, Thommes J, et al. Randomized comparative trial of Doxil vs. adriamycin, bleomycin, and vincristine (ABV) in the treatment of severe AIDS-related Kaposi’s sarcoma (AIDS-KS). 3rd Conf Retro and Opportun Infect 1996:123.
78. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998; 16(2):683-691.
79. Mitsuyasu R, yon Roenn J, Krown S, et al. Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi’s sarcoma (AIDS-KS): AIDS Clinical Trial Group (ACTG) protocol 286 (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997; 16.
80. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15(3):987-993.
81. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin:antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13(7):1777-1785.
82. Gordon AN, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18(17):3093-3100.
83. Gordon A, et al. Interim analysis of a Phase III randomized trial of Doxil/Caelyx (D) versus Topotecan (T) in the treatment of patients with relapsed ovarian cancer. Proc Am Soc Clin Oncol 2000; 19:abst 504, 129a.
84. Ranson MR, Carmichael J, O’Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15(10):3185-3191.
85. Wigler N, Inbar M, et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21:abs. 177.
86. Haran G, Cohen R, Bar LK, et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases [published erratum appears in Biochim Biophys Acta 1994; Feb 23;1190(1):197]. Biochim Biophys Acta 1993; 1151(2):201-215.
87. Druckmann S, Gabizon A, Barenholz Y. Separation of liposome- associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies. Biochim Biophys Acta 1989; 980(3):381-384.